Agenus Inc. - Common Stock (NQ:AGEN)

8.360 +0.030 (+0.36%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 19, 2023

Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering.

Via Benzinga

These 3 Nasdaq Stocks Are on Fire Today: Here's Why ↗

April 17, 2023

A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today.

Via The Motley Fool

Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer

April 17, 2023

From Agenus Inc.

Via Business Wire

Agenus' Investigational Cancer Combo Therapy Shows 33% Durable Responses In Ovarian Cancer ↗

March 27, 2023

Via Benzinga

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

April 12, 2023

From Gain Therapeutics, Inc.

Via GlobeNewswire

Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today ↗

April 04, 2023

Macro headwinds are weighing on risk-laden biotech stocks today.

Via The Motley Fool

Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics

March 30, 2023

From Agenus Inc.

Via Business Wire

Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer

March 27, 2023

From Agenus Inc.

Via Business Wire

Why Agenus Stock Is Slumping This Week ↗

March 23, 2023

The biotech may have to raise capital soon.

Via The Motley Fool

Agenus (AGEN) Q4 2022 Earnings Call Transcript ↗

March 14, 2023

AGEN earnings call for the period ending December 31, 2022.

Via The Motley Fool

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives

March 14, 2023

From Agenus Inc.

Via GlobeNewswire

Illumina, Seagen And Other Big Stocks Moving Higher On Monday ↗

March 13, 2023

U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Earnings Preview For Agenus ↗

March 13, 2023

Via Benzinga

Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement

March 12, 2023

Conference Call Cancelled

From Agenus Inc.

Via GlobeNewswire

Looking Into Agenus's Return On Capital Employed ↗

December 05, 2022

Via Benzinga

Why Shares of Agenus Rose 12.5% on Friday ↗

December 02, 2022

Agenus presented data this week on a combination therapy.

Via The Motley Fool

Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB

March 11, 2023

Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET

From Agenus Inc.

Via GlobeNewswire

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report

February 28, 2023

Conference Call on Tuesday, March 14, 2023 at 8:30 a.m. ET

From Agenus Inc.

Via GlobeNewswire

Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer

February 28, 2023

From Agenus Inc.

Via GlobeNewswire

Agenus to Participate in February Investor Conferences

January 26, 2023

From Agenus Inc.

Via GlobeNewswire

Agenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer Candidate ↗

January 23, 2023

Via Benzinga

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

January 23, 2023

From Agenus Inc.

Via GlobeNewswire

Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference

January 10, 2023

From Agenus Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022 ↗

December 22, 2022

Via Benzinga

Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI

December 21, 2022

From Agenus Inc.

Via GlobeNewswire

7 Hot Stocks to Book Profits In Before 2023 ↗

December 19, 2022

With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in.

Via InvestorPlace

Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma

November 17, 2022

From Agenus Inc.

Via GlobeNewswire

Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference

November 16, 2022

From Agenus Inc.

Via GlobeNewswire

Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗

November 15, 2022

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...

Via Benzinga

Miniso Group, Monday.com And Other Big Gainers From Monday ↗

November 15, 2022

U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 200 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.